PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice
Authors:
- 1 January 2018
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 314 (1) , F122-F131
Abstract
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear hormone receptor that promotes fatty acid β-oxidation (FAO) and oxidative phosphorylation (OXPHOS). We and others have recently shown that PPARα and its target genes are downregulated, and FAO and OXPHOS are impaired in autosomal dominant polycystic kidney disease (ADPKD). However, whether PPARα and FAO/OXPHOS are causally linked to ADPKD progression is not entirely clear. We report that expression of PPARα and FAO/OXPHOS genes is downregulated, and in vivo β-oxidation rate of3H-labeled triolein is reduced in Pkd1RC/RCmice, a slowly progressing orthologous model of ADPKD that closely mimics the human ADPKD phenotype. To evaluate the effects of upregulating PPARα, we conducted a 5-mo, randomized, preclinical trial by treating Pkd1RC/RCmice with fenofibrate, a clinically available PPARα agonist. Fenofibrate treatment resulted in increased expression of PPARα and FAO/OXPHOS genes, upregulation of peroxisomal and mitochondrial biogenesis markers, and higher β-oxidation rates in Pkd1RC/RCkidneys. MRI-assessed total kidney volume and total cyst volume, kidney-weight-to-body-weight ratio, cyst index, and serum creatinine levels were significantly reduced in fenofibrate-treated compared with untreated littermate Pkd1RC/RCmice. Moreover, fenofibrate treatment was associated with reduced kidney cyst proliferation and infiltration by inflammatory cells, including M2-like macrophages. Finally, fenofibrate treatment also reduced bile duct cyst number, cyst proliferation, and liver inflammation and fibrosis. In conclusion, our studies suggest that promoting PPARα activity to enhance mitochondrial metabolism may be a useful therapeutic strategy for ADPKD.Keywords
Funding Information
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (DK102572)
This publication has 37 references indexed in Scilit:
- Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseaseWorld Journal of Hepatology, 2013
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severityJournal of Clinical Investigation, 2012
- MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic PathwaysScience Translational Medicine, 2012
- Macrophages Promote Cyst Growth in Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- Inhibition of Alanine Aminotransferase in Silico and in Vivo Promotes Mitochondrial Metabolism to Impair Malignant GrowthJournal of Biological Chemistry, 2011
- PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney diseaseAmerican Journal of Physiology-Renal Physiology, 2011
- Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networksHuman Molecular Genetics, 2009
- Advances in the pathogenesis and treatment of polycystic kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2009
- Cancer Cell Metabolism: Warburg and BeyondCell, 2008